
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Perspective on the Treatment of Advanced Renal Cell Cancer
A Japanese-American Male With Recurrent RCC
November 2015
September 2017
July 2018
